Table 1 Baseline characteristics in the MSKCC and internal cohorts.
From: KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer
Characteristics | MSKCC cohort | Internal cohort | ||||
|---|---|---|---|---|---|---|
KMT2C-MUT (n = 20) | KMT2-WT (n = 90) | P value | KMT2C-MUT (n = 18) | KMT2C-WT (n = 42) | P value | |
Age, n (%) | ||||||
≥ 65 | 6 (30) | 21 (23) | 0.570 | 2 (11) | 7 (17) | 0.710 |
< 65 | 14 (70) | 69 (77) | 16 (89) | 35 (83) | ||
Sex, n (%) | ||||||
Male | 14 (70) | 48 (53) | 0.217 | 9 (50) | 27 (64) | 0.391 |
Female | 6 (30) | 42 (47) | 9 (50) | 15 (36) | ||
Primary tumor site, n (%) | ||||||
Rectum | 2 (10) | 16 (18) | 0.519 | 0 (0) | 13 (31) | 0.011 |
Colorectal | 18 (90) | 74 (82) | 18 (100) | 29 (69) | ||
Tumor differentiation, n (%) | ||||||
High + medium | – | – | – | 17 (94) | 31 (74) | 0.086 |
Low | – | – | 1 (6) | 11 (26) | ||
MSI status, n (%) | ||||||
MSI-H | 15 (75) | 20 (22) | < 0.0001 | 15 (83) | 22 (52) | 0.041 |
MSS | 5 (25) | 70 (78) | 3 (17) | 20 (48) | ||
